Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | RGS12 | O14924 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13164341 | 0.89 | LMNA (0.53) | MTORRAB9AGRM7GAAL3MBTL1 | |
| SCHEMBL11100775 | 0.85 | MTOR (0.44) | MTORRAB9AGRM7CYP3A4ALOX15 | |
| SCHEMBL23429020 | 0.84 | ACP3 (0.45) | MTORRAB9AGRM7GAAL3MBTL1 | |
| SCHEMBL13164343 | 0.84 | ALDH1A1 (0.54) | GAACYP3A4TDP1PKMMEN1 | |
| SCHEMBL3281034 | 0.83 | MTOR (0.57) | MTORRAB9AGRM7L3MBTL1CYP3A4 | |
| SCHEMBL31067577 | 0.82 | KDM4E (0.40) | GAAL3MBTL1CYP3A4TDP1TEAD4 | |
| SCHEMBL17065061 | 0.82 | KDM4E (0.40) | GAAL3MBTL1CYP3A4TDP1TEAD4 | |
| SCHEMBL21836227 | 0.82 | SIGMAR1 (0.55) | MTORRAB9AGRM7GAAL3MBTL1 | |
| SCHEMBL21836226 | 0.82 | SIGMAR1 (0.55) | MTORRAB9AGRM7GAAL3MBTL1 | |
| SCHEMBL7991731 | 0.80 | ADRA2C (0.48) | MTORRAB9AGRM7L3MBTL1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210236539-A1 | METHOD OF PROPHYLAXIS OF ZIKA VIRUS INFECTION | STARPHARMA PTY LTD (AU) | 2021-08-05 | — | — | US | disclosed |
| US-9636670-B2 | Catalysts, ligands and use thereof | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2017-05-02 | — | — | US | disclosed |
| US-9636670-B2 | Catalysts, ligands and use thereof | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2017-05-02 | — | — | US | disclosed |
| US-9636670-B2 | Catalysts, ligands and use thereof | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2017-05-02 | — | — | US | disclosed |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2017-01-19 | — | — | US | disclosed |
| US-20160074852-A1 | CATALYSTS, LIGANDS AND USE THEREOF | ISIS INNOVATION LIMITED (GB) | 2016-03-17 | — | — | US | disclosed |
| US-20160074852-A1 | CATALYSTS, LIGANDS AND USE THEREOF | ISIS INNOVATION LIMITED (GB) | 2016-03-17 | — | — | US | disclosed |
| EP-2986375-A2 | CATALYSTS, LIGANDS AND USE THEREOF | Isis Innovation Limited (GB) | 2016-02-24 | — | — | EP | disclosed |
| WO-2014170642-A2 | CATALYSTS, LIGANDS AND USE THEREOF | ISIS INNOVATION LIMITED (GB) | 2014-10-23 | — | — | WO | disclosed |
| WO-2014170642-A2 | CATALYSTS, LIGANDS AND USE THEREOF | ISIS INNOVATION LIMITED (GB) | 2014-10-23 | — | — | WO | disclosed |
| US-7501404-B2 | Substituted azetidinones | DAIMED (US) | 2009-03-10 | — | — | US | disclosed |
| US-20080207525-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; bioavailability; coupling; chemical intermediates | PHARMASCIENCE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-20080069812-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents | AEGERA THERAPEUTICS, INC. (CA) | 2008-03-20 | — | — | US | disclosed |
| US-20080069812-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents | AEGERA THERAPEUTICS, INC. (CA) | 2008-03-20 | — | — | US | disclosed |
| WO-2007104162-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS, INC. (CA) | 2007-09-20 | — | — | WO | disclosed |
| US-20070197522-A1 | Dpp-iv inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070105832-A1 | Substituted azetidinones | Cadrenal Therapeutics, Inc. | 2007-05-10 | — | — | US | disclosed |
| EP-0433662-A2 | Acat inhibitors | WARNER-LAMBERT COMPANY (US) | 1991-06-26 | — | — | EP | disclosed |
| US-4958029-A | Process for the production of isoindoline derivatives, novel intermediates and process for their production | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1990-09-18 | — | — | US | disclosed |
| EP-0275064-A2 | Process for the production of isoindoline derivatives, novel intermediates and process for their production | Banyu Pharmaceutical Co., Ltd. (JP) | 1988-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105832-A1 | Substituted azetidinones | F2R, CPA3, CFD | MTOR 3646/4885RAB9A 453/4885GRM7 3307/4885 |
| US-20160074852-A1 | CATALYSTS, LIGANDS AND USE THEREOF | SPR, SQOR, COASY | MTOR 4164/4885RAB9A 3149/4885GRM7 3725/4885 |
| US-20070197522-A1 | Dpp-iv inhibitors | DPP7, DPP4, DPP3 | MTOR 3802/4885RAB9A 3070/4885GRM7 495/4885 |
| US-20080069812-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents | BIRC5, XIAP, BIRC2 | MTOR 1214/4885RAB9A 1461/4885GRM7 4700/4885 |
| US-20080207525-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; bioavailability; coupling; chemical intermediates | BIRC5, XIAP, BAX | MTOR 1462/4885RAB9A 1476/4885GRM7 4738/4885 |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | AGTR2, MME, AGTR1 | MTOR 1126/4885RAB9A 3461/4885GRM7 809/4885 |
| US-20210236539-A1 | METHOD OF PROPHYLAXIS OF ZIKA VIRUS INFECTION | NAPA, CX3CR1, KISS1R | MTOR 4506/4885RAB9A 1532/4885GRM7 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.